Belite Bio, Inc (BLTE)

NASDAQ

$142.37

+$1.05 (0.74%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$141.56$147.08

Open $142.50

52 Week Range

$49.00$161.32

Previous Close $141.32

Market Cap4.97B

Volume121.01K

Avg Volume146.69K

P/E (TTM)-93.95

EPS (TTM)$-1.52

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Belite Bio, Inc

DEC12025

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

Source: GlobeNewsWire•14 days ago

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significa...

DEC12025

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

Source: GlobeNewsWire•14 days ago

DEC12025

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Source: GlobeNewsWire•15 days ago

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced topline results from the global Phase 3 “DRAGON” trial of Tinlarebant, marking the first successful pivotal trial in patients ...

OCT292025

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

Source: GlobeNewsWire•48 days ago

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at...

OCT292025

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Source: GlobeNewsWire•48 days ago

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant un...

OCT152025

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Source: GlobeNewsWire•62 days ago

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today a...